Industries > Pharma > Global Treatment for Neglected Tropical Disease Market 2019-2029

Global Treatment for Neglected Tropical Disease Market 2019-2029

Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease

PAGES: 157
PRODUCT CODE: PHA0396

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0240 Categories: , , Tag:

The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere.

The 157-page report provides clear detailed insight into the Global Treatment for Neglected Tropical Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Treatment for Neglected Tropical Disease market forecasts from 2019-2029

Global Treatment for Neglected Tropical Disease Market 2017-2027

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by disease type:
– Malaria treatments
– Dengue treatments
– Leishmaniasis
– Schistosomiasis
– Lymphatic Filariasis
– Chagas Disease
– Others

For each disease type, the report provides a SWOT analysis, a list of selected drugs and revenue forecasts from 2019-2029 of the leading drugs.

• This report provides revenue forecast for these leading drugs:
– Coartem (Novartis)
– Clindamycin (Pfizer)
– Dengvaxia (Sanofi)
– AmBisome (Gilead Sciences)
– Impavido (Knight Therapeutics)
– ALBENZA (Amedra Pharmaceuticals LLC)

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by regional and national market:
– North America: US and Canada
– Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
– Asia-Pacific: Japan, China, India, Rest of Asia
– Latin America: Brazil, Mexico, Rest of Latin America
– Middle East & Africa: Saudi Arabia, South of Africa, Rest of Middle East & Africa

Each regional market is further broken down by disease type.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the neglected tropical disease market:
– Pfizer, Inc.
– Bayer
– GlaxoSmithKline plc
– Merck & Co., Inc.
– Novartis International AG
– Takeda Pharmaceutical Company Ltd
– Sanofi S.A.
– Eisai Co., Ltd

Buy our report today Global Treatment for Neglected Tropical Disease Market 2019-2029: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ